Overview
Hemas is a Sri Lankan diversified group across consumer, healthcare and mobility, with leading positions in FMCG and pharmaceuticals and stakes in hospitals and travel. The big picture is valuation support and a net‑cash balance sheet following record FY26 earnings, set against Q1 FY27 margin compression in the structurally weak June quarter.
Price performance
HHL closed at LKR 31.20 on 2026-08-07. Over 1 year it rose 0.6% versus the ASPI’s 9.5%.
It is around 40% of its 52‑week range. Trading has been quiet, with 20‑day volume 55% below its 60‑day average.
Valuation
At 6.81x P/E (sector percentile 0), the share screens as the cheapest in diversified holdings. ROE is 15.7%, which helps explain a P/B that reads full versus peers.
The dividend yield is 5.6%. The payout has risen from LKR 0.68 per share in FY2024 to LKR 1.00 in FY2026.
News and sentiment
Coverage has been unusually quiet in the last 30 days at 0.5x its own baseline. Across 90 days we logged 16 material items. The split skewed positive at 9 versus 6 negative.
On 7 Aug, Q1 FY27 updates reported a 21.4% drop in earnings attributable to equity holders to LKR 937 million. Board changes and a final dividend with an ex‑date of 30 Jun were also filed. Earlier, the EPF disclosed a 40 million‑share purchase in 2025 and an ESOS proposal was announced.
Financials
June quarter profitability softened on a like‑for‑like basis. Gross margin was 30.4% versus 30.1% a year ago. Operating margin was 5.7% versus 7.2%. Net margin was 3.7% versus 4.4%.
June is structurally its weakest quarter for operating margin, and the latest print is that seasonal low, so the quarter should be judged against prior Junes rather than against December or March peaks.
Risks
The lead risk is near‑term margin squeeze from input costs and currency: operating margin fell 1.6 points year on year to 5.7% in June.
Execution and cash discipline also matter: cash conversion was 0.83. Liquidity is adequate at a 1.72 current ratio, and interest cover of 13.8x reduces refinancing risk. In addition, 4.0% of profit belongs to minorities, modestly diluting what accrues to HHL shareholders.
Outlook
As at 2026-08-07, the next event is the September‑quarter filing, expected between 28 Oct and 26 Jan. A rebound in operating margin from the June base would support sentiment; further squeeze would argue the other way.
Context: rates have been easing and the rupee broadly steady, while July inflation printed 7.3%, so input costs and pricing traction remain the variables to watch. In healthcare, ongoing policy discussions about local pharma support form a constructive backdrop for a segment that accounts for roughly three‑fifths of Group revenue.